Today's Breaking News
- Vaxart’s Groundbreaking Tablet Influenza Vaccine Generates Protective Antibody Levels in Humans
- Sarepta Therapeutics Announces Eteplirsen Demonstrates a Continued Benefit on Walking Test Through 84 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy
- AstraZeneca and Bristol-Myers Squibb Announce Top Line Results for SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza (saxagliptin)
Latest R&D and Business News
- ALK announces positive outcome of pivotal Phase III trial with new allergy immunotherapy tablet against house dust mite allergy
- Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
- Teva Strengthens Respiratory Franchise with Acquisition of MicroDose Therapeutx
- Intezyne Technologies Expands Its Oncology Pipeline Through Strategic Acquisition of Niiki Pharma
- Takeda and Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival with ADCETRIS® (brentuximab vedotin) Versus Prior Therapy at the International Conference on Malignant Lymphoma
- NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease
- Amarantus Reports Positive Results on MANF Neuroprotective Properties Demonstrated in Preclinical Study in China
- Aurigene and Debiopharm Group™ Report Nomination of Development Candidate Debio 0617B in Oncology
- Celltrion files for approval of CT-P6, breast cancer mAb biosimilar, in Korea
- RemsimaTM extended clinical trial study was disclosed in EULAR 2013
- Karolinska Development AB (publ): Athera and Boehringer Ingelheim enter into an option agreement on a novel therapy for Atherosclerosis
- Kitasato Daiichi Sankyo Vaccine Submits a New Drug Application in Japan for the Cell Culture-Based Pandemic Influenza Vaccine